Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pregnenolone methyl ether - Mapreg

Drug Profile

Pregnenolone methyl ether - Mapreg

Alternative Names: 3-methoxy-pregnenolone - Mapreg; MAP-4343

Latest Information Update: 28 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mapreg
  • Class Antidepressants; Drug withdrawal therapies; Steroids
  • Mechanism of Action Microtubule-associated protein stimulants; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders
  • No development reported Brain injuries; Spinal cord injuries; Substance-related disorders

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for phase-I development in Substance-related disorders in France (PO)
  • 23 Feb 2022 Mapreg withdrew a phase II trial prior to enrolment due to the lack of feasibility because of COVID-19 pandemic for Alcoholism in USA (PO) (NCT04157114)
  • 28 Oct 2021 No recent reports of development identified for phase-I development in Brain injuries in France (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top